|

Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

RECRUITINGSponsored by Duke University
Actively Recruiting
SponsorDuke University
Started2019-09-26
Est. completion2029-09
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations5 sites
View on ClinicalTrials.gov →

NCT04085029

Summary

The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years of age
* Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
* Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
* Patient must sign study-specific informed consent

Exclusion Criteria:

• None

Conditions3

CancerMetastatic CancerOligometastasis

Locations5 sites

Duke Cancer Institute Cary
Cary, North Carolina, 27518
Clinical Trials Office919-668-3726RadOnc-Clinical_Trials@dm.duke.edu
Durham Veterans Administration Health Care System (DVAHCS)
Durham, North Carolina, 27705
Josephine Gaston, RNjosephine.gaston@va.gov
Duke University Medical Center
Durham, North Carolina, 27710
Clinical Trials Office919-668-3726RadOnc-Clinical_Trials@dm.duke.edu
Duke Women's Cancer Care Raleigh
Raleigh, North Carolina, 27607
Clinical Trials Office919-668-3726RadOnc-Clinical_Trials@dm.duke.edu
Duke Raleigh Hospital
Raleigh, North Carolina, 27609
Clinical Trials Office919-668-3726RadOnc-Clinical_Trials@dm.duke.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.